These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29939878)

  • 21. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
    Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
    Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicities associated with immunotherapies for hematologic malignancies.
    Leick MB; Maus MV
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review.
    Amicucci M; Simioli V; De Cecco V; Orlando L; Ciaralli I; Buccino A; Guidi B; Locatelli G; Palmieri C; Piazzalunga M; Proietti R; Pucci A; Botti S
    Semin Oncol Nurs; 2023 Oct; 39(5):151478. PubMed ID: 37544775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know.
    Neill L; Rees J; Roddie C
    Pract Neurol; 2020 Aug; 20(4):285-293. PubMed ID: 32503897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR T-Cell Therapy: Updates in Nursing Management.
    Baer B
    Clin J Oncol Nurs; 2021 Jun; 25(3):255-258. PubMed ID: 34019023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
    Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies.
    McGann M; Velayati A; Roubal K; Granger K; Davis JA; Gaffney KJ; Weeda E; Hashmi H
    Leuk Lymphoma; 2023 Sep; 64(9):1592-1595. PubMed ID: 37287328
    [No Abstract]   [Full Text] [Related]  

  • 31. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
    Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
    Front Immunol; 2021; 12():670286. PubMed ID: 34135898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
    El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
    Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulopathy in CAR-T: Critical concern or mere blip?
    Galli E; Sorà F; Rossi E
    Br J Haematol; 2024 Aug; 205(2):409-410. PubMed ID: 38938123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.
    Halim L; Ajina A; Maher J
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):117-125. PubMed ID: 29909912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
    Gudiol C; Lewis RE; Strati P; Kontoyiannis DP
    Lancet Haematol; 2021 Mar; 8(3):e216-e228. PubMed ID: 33460558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy: A case report.
    Zhang F; Jia XL; Zuo YX; Lu AD; Zhang PF; Xue L; Zhang LP
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29563. PubMed ID: 35044056
    [No Abstract]   [Full Text] [Related]  

  • 38. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
    Anderson MK; Torosyan A; Halford Z
    Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
    Catalá E; Iacoboni G; Vidal-Jordana Á; Oristrell G; Carpio C; Vilaseca A; Cabirta A; Bosch F; Tintoré M; Barba P
    Hematol Oncol; 2022 Aug; 40(3):482-487. PubMed ID: 35139240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-T cell therapy and infection: a review.
    Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.